Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patients
Andreas Pircher, Ferdinand Ploner, Helmut Popper, Wolfgang Hilbe
20100801
2010 Sept 1
Lung Cancer
Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patients
Lung Cancer. 2010 Sept;69(3):265-271, Andreas Pircher, Ferdinand Ploner, Helmut Popper, Wolfgang Hilbe
Abstract
Abstract
In 2002 results of two-phase II studies with the new epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) gefitinib showed not only promising efficacy in second and third line non-small cell lung cancer (NSCLC) therapies but also an excellent tolerability. Since then, thousands of patients have been treated in one of the largest expanded access programs ever performed and the successful application in daily routine led to a preliminary approval of the drug by the U.S. Food and...
